Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

— Polymer-conjugated IL-15 (NKTR-255) induced CD8⁺ T cell and natural killer cell proliferation in vivo —

— NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model —

Excerpt from the Press Release:

SAN FRANCISCO, Nov. 9, 2022 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8⁺ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates.

“The findings published today reinforce the foundational rationale behind the clinical development program we’re pursuing of NKTR-255 enhancing CAR-T cell therapies,” said Jonathan Zalevsky, Ph.D., Chief Research & Development Officer at Nektar. “We are looking forward to progressing our research in combination with cell therapies and are excited to launch our Phase 2/3 clinical trial of NKTR-255 following approved CAR-T cell therapies in patients with relapsed or refractory diffuse large B-cell Lymphoma.”

The data from this publication demonstrate that NKTR-255 not only enhanced in vivo proliferation and accumulation of T and NK cells in non-human primates, but also demonstrated enhanced in vivo antitumor efficacy of human CD19 CAR-T in lymphoma-bearing immunodeficient mice.

Click the button below to read the entire Press Release:

Continue Reading The Press Release